Table 3 Baseline demographics and angiographic characteristics of diabetes and non diabetes population with successful and failed revascularization

Age (years)

70 ± 12

70 ± 13

0.71

66 ± 14

68 ± 13

0.10

Gender (male)

229 (86)

42 (88)

1

339 (96)

65 (90)

0.08

Hypertension

226 (85)

42 (88)

0.83

241 (68)

54 (75)

0.27

Hyperlipidemia

121 (46)

26 (54)

0.35

146 (41)

27 (38)

0.60

Prior stroke

25 (9)

8 (17)

0.13

26 (7)

3 (4)

0.45

PAD

18 (7)

7 (15)

0.08

16 (5)

4 (6)

0.76

Smoking

92 (35)

17 (35)

1.00

161 (46)

30 (42)

0.60

Prior MI

77 (29)

15 (31)

0.73

58 (16)

9 (13)

0.48

Prior PCI

151 (57)

24 (50)

0.43

166 (47)

42 (58)

0.09

Prior CABG

28 (11)

8 (17)

0.22

33 (9)

7 (10)

0.83

LVEF (%)

47 ± 12

47 ± 12

0.92

50 ± 12

48 ± 14

0.36

eGFR, MDRDc (ml/min)

78 ± 36

67 ± 32

0.06

89 ± 29

82 ± 34

0.06

LDL (mg/dl)

98 ± 33

92 ± 30

0.39

106 ± 36

100 ± 34

0.29

HbA1C

7.9 ± 1.7

7.7 ± 1.7

0.57

–

–

–

Non invasive test

0.616

0.068

 Treadmill

50 (19)

6 (13)

80 (23)

7 (10)

 Thallium scan

202 (77)

40 (83)

247 (70)

61 (85)

 Others

12 (5)

2 (4)

27 (7)

4 (5)

OAD

191 (72)

32 (67)

0.62

–

–

–

 Metformin

39 (15)

6 (13)

 Sulphonylurea

15 (6)

5 (11)

 DPP4 inhibitor

5 (2)

5 (11)

 Meglitinide

1 (1)

1 (2)

 Combined regimen

81 (31)

12 (25)

 Combined insulin and OAD

31 (12)

4 (8)

Insulin (%)

55 (21)

13 (27)

0.62

–

–

–

Location of CTO

 LAD

107 (40)

16 (33)

0.42

164 (46)

30 (42)

0.52

 LCx

68 (26)

16 (33),

0.29

91 (26)

21 (29)

0.56

 RCA

138 (52)

30 (63)

0.21

155 (44)

33 (46)

0.80

J CTO score

2.54 ± 1.00

2.66 ± 1.00

0.38

2.31 ± 0.99

2.40 ± 0.89

0.537

Syntax score

18 ± 6

20 ± 7

0.03

19 ± 6

20 ± 7

0.24

MVD

224 (85)

46 (96)

0.04

277 (78)

60 (83)

0.43

Lesion length (mm)

38 ± 18

31 ± 9

0.12

38 + 18

32 + 12

0.05

Lesion width (mm)

3.0 ± 1.6

3.0 ± 0.6

0.96

3.3 + 4.5

3.0 + 0.3

0.72

Primary retrograde

22 (9)

2 (5)

0.85

26 (8)

6 (8)

1.00